Dermatological Drugs - Central & Western Europe

Central & Western Europe

The revenue in the Dermatological Drugs market in Central & Western Europe is projected to reach US$2.46bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.73%, resulting in a market volume of US$3.25bn by 2029.
In global comparison, United States is expected to generate the highest revenue, reaching US$11,670.00m in 2024.
In Central & Western Europe, Germany is leading the market for dermatological drugs with its strong focus on research and development.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Dermatological Drugs market in Central & Western Europe has been growing steadily in recent years.

Customer preferences: Consumers in Central & Western Europe have become increasingly concerned about the appearance of their skin and are more willing to invest in dermatological drugs to improve their skin health. Additionally, an aging population has led to an increase in demand for anti-aging products.

Trends in the market: Germany is the largest market for dermatological drugs in Central & Western Europe, with a high demand for prescription-based products. France and Italy follow closely behind, with a growing trend towards natural and organic skincare products. In the UK, the market for dermatological drugs is driven by a high demand for acne treatments.

Local special circumstances: In France, the market for dermatological drugs is heavily regulated, with strict rules on advertising and promotion. This has led to a focus on word-of-mouth recommendations and a growing trend towards natural and organic skincare products. In Germany, a strong pharmaceutical industry has led to a high demand for prescription-based dermatological drugs.

Underlying macroeconomic factors: The overall growth of the skincare market in Central & Western Europe can be attributed to a growing middle class with higher disposable incomes and a greater awareness of the importance of skincare. Additionally, an aging population has led to an increase in demand for anti-aging products. The COVID-19 pandemic has also had an impact on the market, with a growing demand for at-home skincare products as consumers spend more time indoors.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.